FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)

Simply Wall St.

Jul 06

Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva and secured US FDA priority review ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2649619272"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649619272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649619272?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-06 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649619272","market":"hk","top_or_hot":-1,"title":"FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)","media":"Simply Wall St.","content":"<div>\n<p>Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva and secured US FDA priority review ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/fda-priority-review-for-zilurgisertib-could-be-a-game-change\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 04:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/fda-priority-review-for-zilurgisertib-could-be-a-game-change><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva and secured US FDA priority review ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/fda-priority-review-for-zilurgisertib-could-be-a-game-change\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/fda-priority-review-for-zilurgisertib-could-be-a-game-change","article_id":"2649619272","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/fda-priority-review-for-zilurgisertib-could-be-a-game-change","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649619272","pubTimestamp":1783282789,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva and secured US FDA priority review acceptance for its new drug application, with a decision scheduled for late September 2026.\nThis combination of encouraging data in an ultra-rare indication and accelerated regulatory review could meaningfully broaden Mirum’s rare disease portfolio beyond its existing commercial assets.\nWe’ll now...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","MIRM":"Mirum Pharmaceuticals, Inc."},"translate_title":"FDA对Zilurgisertib的优先审查可能会改变Mirum Pharmaceuticals(MIRM)的游戏规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1.5,"LABU":1.5},"content_text":"Mirum Pharmaceuticals recently reported past positive pivotal phase II results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva and secured US FDA priority review acceptance for its new drug application, with a decision scheduled for late September 2026. This combination of encouraging data in an ultra-rare indication and accelerated regulatory review could meaningfully broaden Mirum’s rare disease portfolio beyond its existing commercial assets. We’ll now examine how the FDA’s priority review for zilurgisertib may reshape Mirum’s rare-disease investment narrative and future growth mix. Outshine the giants: these 16 early-stage AI stocks could fund your retirement.AdvertisementMirum Pharmaceuticals Investment Narrative RecapTo own Mirum, you need to believe its rare disease franchise can justify heavy R&D spend and persistent losses as it matures. The FDA priority review for zilurgisertib adds a meaningful near term catalyst, but it does not remove the core risk around revenue concentration in Livmarli and exposure to pricing and reimbursement pressure. Among recent updates, the VISTAS Phase 2b data for volixibat in primary sclerosing cholangitis stands out. Together with the zilurgisertib filing, it reinforces a near term catalyst cluster across multiple indications while Mirum is still posting large net losses (US$798.8 million in the most recent period) and investing heavily to support future launches. Yet behind the promising FOP data, investors still need to weigh the risk that concentrated rare disease revenues and pricing pressure could... Read the full narrative on Mirum Pharmaceuticals (it's free!)Mirum Pharmaceuticals' narrative projects $1.1 billion revenue and $234.1 million earnings by 2029. This requires 25.9% yearly revenue growth and a $1,032.9 million earnings increase from -$798.8 million today.Uncover how Mirum Pharmaceuticals' forecasts yield a $144.15 fair value, a 15% upside to its current price.Exploring Other PerspectivesMIRM 1-Year Stock Price Chart Some of the most optimistic analysts were already projecting about US$1.3 billion of revenue and US$436.2 million of earnings by 2029, which is far more aggressive than consensus and assumes Mirum’s concentrated rare disease bets pay off despite regulatory and pricing risks; this new FOP milestone could either support that view or prompt you to reassess how confident you really are in those kinds of assumptions.Explore 3 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth 8% less than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.Ready For A Different Approach?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Find 44 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}